ReviewInflammopharmacology2015
Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs.
Review in Inflammopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- The case for etanercept in the management of toxic epidermal necrolysis.Skin health and disease · 2025Review
- Platelets and diseases: signal transduction and advances in targeted therapy.Signal transduction and targeted therapy · 2025Review
- Pharmaceutical aspects of JAK inhibitors: a comparative review.Inflammopharmacology · 2025Review
- Pharmacogenomics of TNF inhibitors.Frontiers in immunology · 2025Review
- Melatonin, an Antitumor Necrosis Factor Therapy.Journal of pineal research · 2025Review
- Thrombotic adverse events associated with TNF-alpha blockers: a real-world pharmacovigilance analysis of the FAERS database.Frontiers in pharmacology · 2025Article
- Health Implications of Microplastic Exposure in Pregnancy and Early Childhood: A Systematic Review.International journal of women's health · 2025Review
- Th17-Derived Cytokines Synergistically Enhance IL-17C Production by the Colonic Epithelium.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Phytochemical Analysis of the Methanolic Extract and Essential Oil from Leaves of Industrial HempPlants (Basel, Switzerland) · 2022Article
- Influence of anti-TNF-α treatment on liver and kidney functions in patients with ankylosing spondylitis: A retrospective longitudinal study.European journal of rheumatology · 2022Article
- Therapeutic Influence on Important Targets Associated with Chronic Inflammation and Oxidative Stress in Cancer Treatment.Cancers · 2021Review
- Infliximab prevents systemic bone loss and suppresses tendon inflammation in a collagen-induced arthritis rat model.Inflammopharmacology · 2021Article
- Anti- and non-tumor necrosis factor-α-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.World journal of diabetes · 2021Review
- Recombinant Soluble TNF-α Receptor Fusion Protein Therapy Reduces Insulin Resistance in Non-Diabetic Active Rheumatoid Arthritis Patients.ACR open rheumatology · 2020Article
- Mast cell degranulation impairs pneumococcus clearance in miceThe World Allergy Organization journal · 2019Article
- New insights on the pathogenesis of endometriosis and novel non-surgical therapiesJournal of the Turkish German Gynecological Association · 2018Article
- Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.Frontiers in immunology · 2018Review
- Leukocytoclastic vasculitis drug reaction to certolizumab pegol.Proceedings (Baylor University. Medical Center) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor (TNF) is a key regulator of inflammatory processes in several immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis and psoriatic arthritis. Inactivating TNF has been found to be a plausible approach in treating these conditions. Two major strategies have been adopted by scientists to inactivate TNF: one is to use monoclonal antibodies (mAbs) that bind to TNF, and the other is to use fusion proteins that bind to TNF, both inactivate TNF and help to prevent TNF-mediated inflammatory processes. Monoclonal antibodies (mAbs) are biological products that selectively bind to specific antigen molecules, and fusion proteins are soluble receptors that bind to TNF. These types of drugs are generally known as biologics and there has been an explosion in the development and testing of biologics since the 1994 US approval and launch of abciximab, a mAb that binds to GPIIb/IIIa on platelets. Anti-TNF drugs that are currently approved by FDA for treating inflammatory conditions include adalimumab, certolizumab pegol, golimumab, infliximab and etanercept. Since these agents are complex protein molecules, the pharmacodynamics and pharmacokinetics of these drugs are different from small-molecule anti-inflammatory agents. This review focuses on the pharmaceutical aspects of these drugs such as mechanism of action, adverse effects, pharmacokinetics and drug interactions. An effort was also taken to compare the pharmacodynamics and pharmacokinetic properties of these drugs, with the available data at this time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.